Braun Stacey Associates Inc. Sells 9,343 Shares of Colgate-Palmolive Company $CL

Braun Stacey Associates Inc. lowered its holdings in shares of Colgate-Palmolive Company (NYSE:CL) by 4.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 223,790 shares of the company’s stock after selling 9,343 shares during the quarter. Braun Stacey Associates Inc.’s holdings in Colgate-Palmolive were worth $17,684,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Pacer Advisors Inc. raised its position in shares of Colgate-Palmolive by 3,052.2% during the 3rd quarter. Pacer Advisors Inc. now owns 2,697,047 shares of the company’s stock valued at $215,602,000 after buying an additional 2,611,485 shares in the last quarter. Diamond Hill Capital Management Inc. increased its stake in Colgate-Palmolive by 46.7% during the third quarter. Diamond Hill Capital Management Inc. now owns 8,077,549 shares of the company’s stock worth $645,719,000 after acquiring an additional 2,572,796 shares during the last quarter. Amundi raised its position in Colgate-Palmolive by 41.6% during the third quarter. Amundi now owns 6,294,445 shares of the company’s stock valued at $487,505,000 after purchasing an additional 1,850,412 shares during the period. Two Sigma Investments LP lifted its stake in shares of Colgate-Palmolive by 360.9% in the 3rd quarter. Two Sigma Investments LP now owns 2,126,249 shares of the company’s stock valued at $169,972,000 after purchasing an additional 1,664,949 shares during the last quarter. Finally, Balyasny Asset Management L.P. boosted its holdings in shares of Colgate-Palmolive by 50,879.7% in the 2nd quarter. Balyasny Asset Management L.P. now owns 1,193,435 shares of the company’s stock worth $108,483,000 after purchasing an additional 1,191,094 shares during the period. 80.41% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Colgate-Palmolive

In other news, CFO Stanley J. Sutula III sold 97,843 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $94.27, for a total value of $9,223,659.61. Following the completion of the sale, the chief financial officer owned 55,310 shares of the company’s stock, valued at approximately $5,214,073.70. This represents a 63.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Panagiotis Tsourapas sold 15,000 shares of Colgate-Palmolive stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $97.81, for a total transaction of $1,467,150.00. Following the transaction, the chief operating officer directly owned 10,415 shares in the company, valued at approximately $1,018,691.15. The trade was a 59.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 184,683 shares of company stock worth $17,486,693. 0.34% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on CL. TD Cowen restated a “hold” rating and issued a $85.00 price target on shares of Colgate-Palmolive in a research report on Tuesday, March 31st. Jefferies Financial Group raised their target price on shares of Colgate-Palmolive from $85.00 to $91.00 and gave the stock a “hold” rating in a report on Monday, February 2nd. Rothschild & Co Redburn set a $93.00 price target on shares of Colgate-Palmolive in a research note on Friday, February 13th. Barclays upped their price target on shares of Colgate-Palmolive from $83.00 to $88.00 and gave the company an “equal weight” rating in a report on Tuesday, February 3rd. Finally, Evercore raised their price objective on shares of Colgate-Palmolive from $94.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, February 2nd. Eleven investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.19.

Colgate-Palmolive Stock Down 0.1%

Shares of NYSE:CL opened at $85.04 on Friday. The business’s 50 day moving average is $91.10 and its 200 day moving average is $83.46. The stock has a market cap of $68.23 billion, a P/E ratio of 32.46, a price-to-earnings-growth ratio of 3.91 and a beta of 0.34. Colgate-Palmolive Company has a 52-week low of $74.54 and a 52-week high of $99.33. The company has a quick ratio of 0.54, a current ratio of 0.83 and a debt-to-equity ratio of 18.82.

Colgate-Palmolive (NYSE:CL) last issued its earnings results on Friday, January 30th. The company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.91 by $0.04. The business had revenue of $5.23 billion during the quarter, compared to analysts’ expectations of $5.13 billion. Colgate-Palmolive had a return on equity of 353.72% and a net margin of 10.45%.The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.91 EPS. Sell-side analysts predict that Colgate-Palmolive Company will post 3.75 EPS for the current year.

Colgate-Palmolive Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Monday, April 20th will be given a dividend of $0.53 per share. This is a positive change from Colgate-Palmolive’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.5%. Colgate-Palmolive’s payout ratio is 79.39%.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.